Zelluna Activates First Clinical Site for ZIMA-101, Advancing Solid Tumor Therapy Trial
Event summary
- Zelluna ASA has activated its first clinical site for the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust in the UK.
- The trial evaluates ZI-MA4-1, Zelluna’s lead TCR-NK product candidate for solid cancers.
- The Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) approved the Clinical Trial Application (CTA) for ZIMA-101 on 20 February 2026.
- Activation of the second clinical site, The Royal Marsden, is expected soon.
- Initial clinical data from the ZIMA-101 study is anticipated from mid-2026.
The big picture
Zelluna’s activation of the first clinical site for ZIMA-101 marks a critical step in the development of its TCR-NK therapy for solid tumors. The transition from clinical preparation to active trial execution is a strategic milestone, positioning Zelluna to potentially lead in the emerging field of allogeneic cell therapies. The company’s focus on advancing patient screening and dosing underscores its commitment to delivering innovative treatments for solid cancers, a segment with significant unmet medical needs.
What we're watching
- Clinical Execution
- The pace at which Zelluna advances patient screening and dosing will determine the timeline for initial data readouts.
- Regulatory Dynamics
- Whether the MHRA and REC approvals will facilitate smoother activation of additional clinical sites.
- Competitive Positioning
- How Zelluna’s progress with ZI-MA4-1 will impact its standing in the TCR-NK therapy space.
Related topics